Loading…
Harvard Bioscience, Inc. is projected to rise to $7.31 by 2027, a +19% move from its current price of $6.14. HBIO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/13/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 15 | $5.95 | $6.14 | $6.34 | +0.04% |
| Jul 16 | $5.88 | $6.14 | $6.42 | +0.07% |
| Jul 17 | $5.82 | $6.15 | $6.49 | +0.11% |
| Jul 18 | $5.77 | $6.15 | $6.55 | +0.14% |
| Jul 19 | $5.73 | $6.15 | $6.60 | +0.18% |
| Jul 20 | $5.70 | $6.15 | $6.65 | +0.21% |
| Jul 21 | $5.66 | $6.16 | $6.69 | +0.25% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.66 | $6.16 | $6.69 | +0.25% |
| Week 2 | $5.49 | $6.17 | $6.94 | +0.50% |
| Week 3 | $5.36 | $6.19 | $7.15 | +0.75% |
| Week 4 | $5.25 | $6.20 | $7.32 | +1.00% |
| Week 5 | $5.16 | $6.22 | $7.49 | +1.25% |
| Week 6 | $5.08 | $6.23 | $7.64 | +1.51% |
| Week 7 | $5.01 | $6.25 | $7.79 | +1.76% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands.
Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Harvard Bioscience, Inc. (HBIO) operates in the Healthcare space and trades with a current price of $6.14 and a market capitalization of $27.69M. It holds a ranking of 4753 among listed securities.
The stock sits within the Healthcare sector, and the near-term technical picture shows a constructive setup with a bullish tilt in the longer run based on its forecast path.
A major floor 29.8% below — a decisive break under it would weaken the trend.
The nearest floor, 4.4% below — buyers have tended to step in here.
The nearest ceiling, 8.1% above — a clean break opens room to run.
A major ceiling 17.9% above — clearing it would confirm fresh momentum.
Key HBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.33 | Sell | $6.24 | Sell |
| MA 10 | $6.22 | Sell | $6.22 | Sell |
| MA 20 | $6.14 | Buy | $6.16 | Sell |
| MA 50 | $6.09 | Buy | $6.06 | Buy |
| MA 100 | $5.83 | Buy | $5.96 | Buy |
| MA 200 | $5.81 | Buy | $6.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.09 | Neutral |
| Stoch RSI (14) | 12.35 | Buy |
| CCI (20) | 0.23 | Neutral |
| Williams %R (14) | -73.13 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 2.16 | Buy |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 26.87 | Neutral |
| TRIX (15) | 0.12 | Buy |
| Awesome (5,34) | 0.22 | Buy |
| Ultimate (7,14,28) | 52.33 | Neutral |
| Momentum (10) | 0.18 | Buy |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 6.33 | Sell |
| ADX (14) | 7.19 | Neutral |
| ATR (14) | 0.16 | Info |
The 30-day picture shows the stock trading within a $4.99 to $7.55 range, with the latest price near the middle. The RSI(14) is 50, indicating balanced momentum, while the price is above both the 50-day and 200-day moving averages at $6.09 and $5.81 respectively, suggesting a mild near-term bias. Support is at $5.87 and resistance at $6.64, framing a tight, sideways posture near the current level at $6.14.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.31 | $6.14 | $7.80 | 0% | Neutral | |
| $5.74 | $7.31 | $9.91 | +19% | Neutral | |
| $6.18 | $8.13 | $11.49 | +32% | Bullish | |
| $6.67 | $9.03 | $13.17 | +47% | Bullish | |
| $6.40 | $8.87 | $13.29 | +44% | Bullish | |
| $5.90 | $8.36 | $12.83 | +36% | Bullish | |
| $6.15 | $8.90 | $13.95 | +45% | Bullish | |
| $6.86 | $10.11 | $16.16 | +65% | Bullish | |
| $8.03 | $12.05 | $19.61 | +96% | Bullish | |
| $8.16 | $12.48 | $20.63 | +103% | Bullish | |
| $10.16 | $16.85 | $29.82 | +174% | Bullish | |
| $13.98 | $26.72 | $52.19 | +335% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $4.31 | $6.14 | $7.31 | +0.00% |
| August 2026 | $5.12 | $6.07 | $7.40 | -1.15% |
| September 2026 | $5.31 | $6.34 | $7.83 | +4.50% |
| October 2026 | $5.40 | $6.50 | $8.11 | +2.44% |
| November 2026 | $5.17 | $6.26 | $7.88 | -3.66% |
| December 2026 | $5.05 | $6.14 | $7.80 | -1.83% |
Click any year to see its month-by-month HBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, HBIO could reach as high as $7.80, with a base case around $6.14 and support toward $4.31 — roughly 0% from $6.14. A consolidation phase looks the most probable path here.
Expect HBIO to range from $5.74 to $9.91 through 2027. The $7.31 average target implies a +19% move from current prices. That is up +19% on the projected 2026 average. Price action looks broadly range-bound.
The HBIO price prediction for 2028 points to an average of $8.13 (low $6.18, high $11.49) — a potential gain of +32% on today's $6.14. Buyers look set to stay in control over this stretch.
In 2029, HBIO is projected to trade between $6.67 and $13.17, averaging $9.03 — a potential gain of +47% from today's $6.14. That is up +11% on the projected 2028 average. Momentum favours further upside here.
Harvard Bioscience, Inc.'s 2030 outlook centres on $8.87, within a $6.40 to $13.29 range. That is -2% versus the projected 2029 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, HBIO could reach as high as $12.83, with a base case around $8.36 and support toward $5.90 — roughly +36% from $6.14. Momentum favours further upside here.
Expect HBIO to range from $6.15 to $13.95 through 2032. The $8.90 average target implies a +45% move from current prices. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The HBIO price prediction for 2033 points to an average of $10.11 (low $6.86, high $16.16) — a potential gain of +65% on today's $6.14. Momentum favours further upside here.
In 2034, HBIO is projected to trade between $8.03 and $19.61, averaging $12.05 — a potential gain of +96% from today's $6.14. That is up +19% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Harvard Bioscience, Inc.'s 2035 outlook centres on $12.48, within a $8.16 to $20.63 range. That is up +4% on the projected 2034 average. That marks a +103% change versus current levels. Momentum favours further upside here.
By 2040, HBIO could reach as high as $29.82, with a base case around $16.85 and support toward $10.16 — roughly +174% from $6.14. Buyers look set to stay in control over this stretch.
Expect HBIO to range from $13.98 to $52.19 through 2050. The $26.72 average target implies a +335% move from current prices. That is up +59% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in HBIO today (≈ 162.86645 HBIO) could be worth
$4,352.21
+$3,352.21 (+335%) by 2050 · US Dollar
Based on the average projected HBIO price of $26.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HBIOwould be worth at today's price.
$1,000 invested in HBIO on Jul 10, 2025 (≈ 217.391309 HBIO) would be worth
$1,334.78
+$334.78 (+33.5%) today · 1.33× · US Dollar
Based on a HBIO entry price of $4.6 vs. today's $6.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.15 | $998.37 | -0.2% |
| 1 month ago | $6.2 | $990.32 | -1.0% |
| 3 months ago | $4.31 | $1,424.59 | +42.5% |
| 6 months ago | $6.2 | $990.32 | -1.0% |
| 1 year ago | $4.6 | $1,334.78 | +33.5% |
| All time (5.0y) ago | $76.1 | $80.68 | -91.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HBIO forecast.
Our base-case forecast reaches $12.00 around 2034.
Implied market cap at $12.00: $54.12M
The multi-year forecast outlines a bullish trajectory with rising averages and ROIs, anchored by key milestones. By 2030, the average price is projected to $8.87 with an estimated ROI of 44.5%. The path continues toward 2040, where the average is seen at $16.85 and the ROI rises to 174.4%.
By 2050, the forecast shows an average of $26.75 with an ROI of 335.6%, suggesting substantial long-term upside while recognizing these are estimates, not guarantees. Early years show modest gains (2026 avg $6.14, ROI 0) followed by stronger moves into the late 2020s and beyond, with 2040 and 2050 year marks marking the most pronounced upside. As with any forecast, actual results depend on market conditions, execution, and external factors affecting the healthcare and life-science equipment sector.
Tap a question to reveal the answer.
2030: min $6.40, avg $8.87, max $13.30; ROI 44.5%.
The forecast shows a path of higher averages and returns, with 2026 avg $6.14 (ROI 0) and 2050 avg $26.75 (ROI 335.6%). These are estimates, not guarantees, and depend on future market conditions.
Yes. The forecast max by 2040 is $29.82 and by 2050 is $52.24, while the 2040 average is $16.85, indicating a $20 level could be reached within the projected range.
Current price is $6.14; Market cap is $27.69M.
2027: min $5.75, avg $7.33, max $9.93; ROI 19.4%.
Harvard Bioscience, Inc. Community Discussion
0Share your Harvard Bioscience, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.